MGI Expands Cancer Care Line Via Agreement With Alpharma For Kadian
This article was originally published in The Pink Sheet Daily
Executive Summary
Licensing deal will add cancer pain therapy to Aloxi anti-emetic franchise. Aloxi sales now projected to reach $150 mil. for the year. MGI is discussing “several” additional licensing deals in cancer field.